Akèy › Kansè Metastatik › Texas › Houston
Etid klinik pou Kansè Metastatik nan Houston, TX
104 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Lyndon Baines Johnson General Hospital, Houston
- UT MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Ap rekriteFaz 3
- Research Site, Houston
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Ap rekriteFaz 1/2
- University of Texas - MD Anderson Cancer Center, Houston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
- ALX Center 5, Houston
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Texas M.D. Anderson Cancer Center, Houston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Oncology Consultants P.A., Houston
- Oncology Consultants P.A., Houston
- Texas Oncology - Gulf Coast, Houston
- ak 7 plis
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
Ap rekriteVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Ap rekriteFaz 1/2
- Baylor College of Medicine, Houston
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Kelsey Research Foundation, Houston
- Kelsey-Seybold Clinic - North Houston Campus, Houston
- Texas Oncology - Gulf Coast, Houston
- ak 5 plis
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- Houston Methodist Hospital, Houston
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
- NEXT Oncology, Houston
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Oncology Consultants, P.A., Houston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
SLV-154 Treatment of Advanced Cancers
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
- Oncology Consultants, Houston
A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
Ap rekriteFaz 1/2
- NEXT Houston, Houston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Ap rekriteFaz 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- ak 1 plis
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
CREO - Microwave Ablation Feasibility Study
Ap rekrite
- Memorial Hermann-Texas Medical Center, Houston
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Ap rekriteFaz 1
- Houston Methodist Hospital ( Site 0103), Houston
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson, Houston
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Lumi Research, Houston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Ap rekriteFaz 2
- UT MD Anderson Cancer Center, Houston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Houston
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Houston
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Ap rekriteFaz 2
- Research Site, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Ap rekriteFaz 1/2
- Crinetics Study Site, Houston
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Houston
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #129, Houston
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
Ap rekrite
- MD Anderson Cancer Center, Houston
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Ap rekrite
- M D Anderson Cancer Center, Houston
A Study of PYX-201 in Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- Houston Methodist Cancer Center, Houston
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #9, Houston
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Ap rekriteFaz 2
- Michael E. DeBakey VA Medical Center, Houston
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Houston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- University of Texas, MD Anderson Cancer Center, Houston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Ap rekriteFaz 1
- Oncology Consultants, P.A., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Ap rekriteFaz 2
- M.D. Anderson Children's Cancer Hospital, Houston
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center, Houston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Ap rekriteFaz 2/3
- The University of Texas MD Anderson Cancer Center, Houston
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Ap rekrite
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- MD Anderson Cancer Center, Houston
- Oncology Consultants, Houston
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Ap rekriteFaz 2
- Houston Methodist Neal Cancer Center, Houston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- The University Of Texas Md Anderson Cancer Center, Houston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Oncology Consultants, Houston
- Next Oncology, Houston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ap rekriteFaz 3
- The Univeristy of Texas Md Anderson Cancer Center, Houston
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- Houston Metro Urology, Houston
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
Ap rekriteFaz 2
- The University of Texas Health Science Center at Houston, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
HPV Vaccine, Imiquimod, and Metformin Combination Trial
Ap rekriteFaz 2
- Baylor St. Luke's Medical Center- Dan L. Duncan Comprehensive Cancer Center, Houston
- Harris Health Smith Clinic, Houston
Etid Kansè Metastatik nan lòt vil
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
- Seattle, WA39 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
- Karsinòm selil skuamèz tèt ak kou47 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.